PRESS RELEASE published on 01/17/2024 at 22:00, 2 years 9 months ago Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split") Zomedica Corp. (NYSE American:ZOM), a veterinary health company, announced a record revenue for the fourth quarter of 2023 and full year 2023, driven by strong performance across its product lines. The company expects to continue its growth momentum in 2024 with the introduction of formal financial guidance. Additionally, Zomedica will be seeking approval for an 80-1 reverse stock split to generate long-term shareholder value. The Company will be hosting a conference call to provide more details on its business update on Wednesday, January 17, 2024, at 4:30 p.m. Eastern Time. Revenue Growth Zomedica Corp Veterinary Health Company Financial Guidance Reverse Stock Split
PRESS RELEASE published on 01/10/2024 at 12:30, 2 years 9 months ago Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of Sharehol Zomedica Corp., a veterinary health company, will host a conference call on January 17, 2024, to provide a business update, including 2023 revenue and cash position, and discuss the upcoming Share Consolidation and Special Virtual-Only Meeting of Shareholders. For more information and to join the call, visit zomedica.com. Conference Call Zomedica Corp Veterinary Health Company Business Update Share Consolidation
PRESS RELEASE published on 01/04/2024 at 12:30, 2 years 10 months ago Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. Zomedica Corp PulseVet Electro-hydraulic Shock Wave Therapy Veterinary Health Company Canine Patients Electro-hydraulic Shock Wave Therapy
PRESS RELEASE published on 12/18/2023 at 12:30, 2 years 10 months ago Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
PRESS RELEASE published on 12/06/2023 at 12:30, 2 years 11 months ago Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners Zomedica announces presentation of clinical data in support of new indications for Pulsevet shock wave therapy at annual meeting of American Association of Equine Practitioners Zomedica Pulsevet Shock Wave Therapy Veterinary Health Clinical Data
PRESS RELEASE published on 11/28/2023 at 12:30, 2 years 11 months ago Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
PRESS RELEASE published on 11/20/2023 at 12:30, 2 years 11 months ago Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
PRESS RELEASE published on 11/13/2023 at 22:20, 2 years 11 months ago Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
PRESS RELEASE published on 11/02/2023 at 11:30, 3 years ago Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
PRESS RELEASE published on 10/10/2023 at 06:00, 3 years 1 month ago Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
Published on 11/10/2026 at 08:00, 1 hour 11 minutes ago PEL 82 - QatarEnergy to Acquire 25% Participating Interest from Chevron
Published on 11/10/2026 at 02:45, 6 hours 26 minutes ago Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:00, 10 hours 11 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 10 hours 39 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/10/2026 at 09:05, 6 minutes ago Cepheid Achieves CE Marking Under IVDR for Xpert® Respiratory Panel
Published on 11/10/2026 at 09:05, 6 minutes ago Jackery Black Friday 2026: Up to 58% Off Explorer v2 Portable Power Stations and Solar Generators, Starting at Just £378
Published on 11/10/2026 at 07:00, 2 hours 11 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 2 hours 11 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 14 hours 41 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 14 hours 41 minutes ago Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF